Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 09, 2026 13:00 ET | Source: DelveInsight Business Research LLP

Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline Overview: Insights into 80+ Leading Companies and 100+ Novel Treatments | DelveInsight

New york, USA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline Overview: Insights into 80+ Leading Companies and 100+ Novel Treatments | DelveInsight ...
February 09, 2026 12:30 ET | Source: AstuteAnalytica India Pvt. Ltd.

Idiopathic Pulmonary Fibrosis Market Poised to Reach US$ 6,736.49 Million by 2035 as Late-Stage Pipelines and Novel Mechanisms Transform Treatment Outcomes | Astute Analytica

Chicago, Feb. 09, 2026 (GLOBE NEWSWIRE) -- The global Idiopathic pulmonary fibrosis market generated US$ 2,970.69 million in 2025 and is estimated to reach US$ 6,736.49 million by 2035, growing at a...
February 07, 2026 15:40 ET | Source: F. Hoffmann-La Roche Ltd

Roche’s fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in...
February 05, 2026 16:05 ET | Source: Adaptive Biotechnologies

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results

SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
February 03, 2026 07:53 ET | Source: Research and Markets

Antibody Drug Conjugates (ADC) Market Forecasts 2026-2030 with Executive and Consultant Guides - Fast-Tracking, Funding Availability, and Targeted Solutions Spurs Expansion

Dublin, Feb. 03, 2026 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Market Forecasts (2026-2030) by Cancer, Payload, Target, Product, User and Country/Region with Executive and Consultant...
February 03, 2026 06:45 ET | Source: Pyxis Oncology

Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity

BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a...
January 29, 2026 08:00 ET | Source: Breakthru Medicine

Breakthru Medicine emerges from stealth with $60M Series A for cancer drug development

Breakthru Medicine emerges from stealth with $60M Series A in cancer drug development
January 29, 2026 02:30 ET | Source: Enterome

Enterome appoints leading hematologist and IFLI Executive Partner Mehrdad Mobasher, M.D., M.P.H., to its Board of Directors

Dr. Mobasher held several executive roles in industry, most recently CMO at BeiGeneIFLI contributed up to $9 million to Enterome’s private funding round in 2025Enterome has announced a series of...
January 29, 2026 01:00 ET | Source: F. Hoffmann-La Roche Ltd

[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche erzielt starkes Jahresergebnis für 2025 mit Verkaufswachstum von 7%

Konzernverkäufe stiegen um 7%1 zu konstanten Wechselkursen (CER; 2% in CHF) dank hoher Nachfrage nach Medikamenten und diagnostischen Lösungen.Im vierten Quartal nahm der Umsatz um 8% zu und...
January 29, 2026 01:00 ET | Source: F. Hoffmann-La Roche Ltd

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth

Group sales grew by 7%1 at constant exchange rates (CER; 2% in CHF), driven by strong demand for medicines and diagnostic solutions.Sales in the fourth quarter increased by 8%, reflecting the positive...